• Jushi Holdings (JUSH) is set to acquire the remaining 25 per cent interest in TGS Holdings Illinois
  • The company originally acquired 75 per cent of TGS at the end of January
  • With adult-use now legalized in the state, Illinois has seen over C$39.2 million in recreational cannabis sales
  • Shares in Jushi are currently trading at C$1.69, with a market cap of C$154.86 million

Jushi Holdings (JUSH) has entered an agreement to acquire the remaining 25 per cent stake in TGS Holdings Illinois.

On January 30, Jushi announced that it had, through its wholly owned subsidiary Jushi Inc., acquired a 75 per cent interest in TGS Illinois, which owns and operates two medical dispensaries in Sauget and Normal.

There are currently 55 medical dispensaries operating in Illinois, and each has the option to add a second retail location to act as an ‘adult-use’ outlet.

Jushi plans to exercise its right to add adult-use locations and has already received approval for its Sauget store.

“As the sole owner of two medical dispensaries with the opportunity to turn adult-use as well as expand to four locations, we believe in our investment into the Illinois market and the demand that exists in this state,” said Jushi CEO, Jim Cacioppo.

“With our entry into Illinois, we continue Jushi’s mission to expand across limited license states and municipalities coast-to-coast.”

With adult-use approved at the beginning of this year, Illinois has seen over C$39.2 million in sales of recreational cannabis in January alone, equivalent to C$3.07 in sales per resident.

The Jushi-TGS agreement is all but set in stone, with the exception of regulatory approval from the Illinois Department of Financial and Professional Regulation.

Shares in Jushi are currently trading at C$1.69, with a market cap of C$154.86 million.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.